Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells

Journal of Clinical Investigation

Volumn 119, Issue 7, 2009, Pages 2042-2051

  Roberts, Wendy K ^a   Deluca, Ilana J ^a   Thomas, Ashby ^a   Fak, John ^a   Williams, Travis ^a   Buckley, Noreen ^a   Dousmanis, Athanasios G ^a   Posner, Jerome B ^b   Darnell, Robert B ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELAVL4 PROTEIN, HUMAN; EPITOPE; GAMMA INTERFERON; HU ANTIGEN; INTERLEUKIN 13;

AGED; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOLOGY; LUNG TUMOR; MALE; MIDDLE AGED; PARANEOPLASTIC NEUROPATHY; TUMOR CELL LINE;

AGED; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES; FEMALE; GENE EXPRESSION PROFILING; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-13; LUNG NEOPLASMS; MALE; MIDDLE AGED; PARANEOPLASTIC CEREBELLAR DEGENERATION;

EID: 68449095394     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/jci36131     Document Type: Article

References (39)

1. Darnell, R.B. 1996. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity and the brain. Proc. Natl. Acad. Sci. U. S. A. 93:4529-4536.
2. Darnell, R.B., Furneaux, H.M., and Posner, J.B. 1991. Antiserum from a patient with cerebellar degeneration identifies a novel protein in Purkinje cells, cortical neurons, and neuroectodermal tumors. J. Neurosci. 11:1224-1230.
3. Darnell, R.B., and Posner, J.B. 2003. Paraneoplastic syndromes involving the nervous system. N. Engl. J. Med. 349:1543-1554.
4. Darnell, R.B., and Posner, J.B. 2006. Paraneoplastic syndromes affecting the nervous system. Semin. Oncol. 33:270-298.
5. Graus, F., Elkon, K.B., Cordon-Cardo, C., and Posner, J.B. 1986. Sensory neuronopathy and small cell lung cancer; antineuronal antibody that also reacts with the tumor. Am. J. Med. 80:45-52.
6. Roberts, W.K., and Darnell, R.B. 2004. Neuroimmunology of the paraneoplastic neurological degenerations. Curr. Opin. Immunol. 16:616-622.
7. Szabo, A., et al. 1991. HuD, a paraneoplastic encephalomyelitis antigen contains RNA-binding domains and is homologous to Elav and sex lethal. Cell. 67:325-333.
8. Ma, W.J., Cheng, S., Campbell, C., Wright, A., and Furneaux, H. 1996. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J. Biol. Chem. 271:8144-8151.
9. Myer, V.E., Fan, X.H.C., and Steitz, J.A. 1997. Identification of HuR as a protein implicated in AUUUAmediated mRNA decay. EMBO J. 16:2130-2139.
10. Okano, H.J., and Darnell, R.B. 1997. A hierarchy of Hu RNA binding proteins in developing and adult neurons. J. Neurosci. 17:3024-3037.
11. Albert, M.L., et al. 1998. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4:1321-1324.
12. Albert, M.L., Austin, L.M., and Darnell, R.B. 2000. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann. Neurol. 47:9-17.
13. Darnell, R.B., and Albert, M.L. 2000. cdr2-specific CTLs are detected in the blood of all patients with paraneoplastic cerebellar degeneration analyzed. Ann. Neurol. 48:270-271.
14. Santomasso, B.D., et al. 2007. A T-cell receptor associated with naturally occurring human tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 104:19073-19078.
15. de Beukelaar, J.W., et al. 2007. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies. Cancer Immunol. Immunother. 56:1501-1506.
16. Plonquet, A., et al. 2003. Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J. Neuroimmunol. 142:93-100.
17. Rousseau, A., et al. 2005. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J. Neurooncol. 71:231-236.
18. Tanaka, M., et al. 2002. Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J. Neurol. Sci. 201:9-12.
19. Dalmau, J., Furneaux, H.M., Gralla, R.J., Kris, M.G., and Posner, J.B. 1990. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann. Neurol. 27:544-552.
20. Darnell, R.B., and Posner, J.B. 2003. Observing the invisible: successful tumor immunity in humans. Nat. Immunol. 4:201.
21. Bachinsky, M.M., et al. 2005. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Cancer Immun. 5:6.
22. Weichold, F.F., et al. 2007. Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis. Genes Immun. 8:334-343.
23. Newberg, M.H., et al. 1996. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J. Immunol. 156:2473-2480.
24. Steinman, L. 2007. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13:139-145.
25. Sad, S., Marcotte, R., and Mosmann, T.R. 1995. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity. 2:271-279.
26. Bhattacharjee, A., et al. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U. S. A. 98:13790-13795.
27. Rauer, S., and Andreou, I. 2002. Tumor progression and serum anti-HuD antibody concentration in patients with paraneoplastic neurological syndromes. Eur. Neurol. 47:189-195.
28. Seder, R.A., et al. 1992. CD8+ T cells can be primed in vitro to produce IL-4. J. Immunol. 148:1652-1656.
29. Salgame, P., et al. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science. 254:279-282.
30. Maggi, E., et al. 1994. Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J. Exp. Med. 180:489-495.
31. Shi, N., et al. 2007. Increased IL-13-producing T cells in ALS: positive correlations with disease severity and progression rate. J. Neuroimmunol. 182:232-235.
32. Koebel, C.M., et al. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450:903-907.
33. Dunn, G.P., Old, L.J., and Schreiber, R.D. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21:137-148.
34. Coyle, A.J., et al. 1995. Virus-specific CD8+ cells can switch to interleukin 5 production and induce airway eosinophilia. J. Exp. Med. 181:1229-1233.
35. Punnonen, J., Yssel, H., and de Vries, J.E. 1997. The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells. J. Allergy Clin. Immunol. 100:792-801.
36. Sad, S., et al. 1997. Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity. Eur. J. Immunol. 27:914-922.
37. Mosmann, T.R., and Sad, S. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:138-146.
38. Firat, H., et al. 1999. H-2 class I knockout, HLAA2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur. J. Immunol. 29:3112-3121.
39. He, T.C., et al. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 95:2509-2514.